Prof. Atanas G. Atanasov is mainly interested in understandingthe molecular mechanisms regulating health and disease and the biological effects of natural products and food constituents.
Prof. Atanasov first studied at the University of Sofia, Bulgaria, and then later on received a PhD degree in Biochemistry from the University of Bern, Switzerland. Since 2008, he became a senior researcher at Department of Pharmacognosy, University of Vienna, Austria, where he was actively involved in the execution of the Austrian national network “Drugs From Nature Targeting Inflammation” (DNTI), a collaborative research project which has been financed with >3 000 000 Euro from the Austrian Science Fund (FWF) to support the identification and characterization of plant-derived natural products counteracting inflammatory responses.
Prof. Atanasov has also been appointed as a beneficiary member and actively contributed to the European Commission 7th Framework Program (FP7) network consortium “Good Practice in Traditional Chinese Medicine (GP-TCM)”. In recognition of his overall achievements, Prof. Atanasov has been awarded in 2012 with a “Focus of Excellence” distinctionby the Faculty of Life Sciences, University of Vienna.
In 2016, Prof. Atanasov accomplished his Habilitation in Pharmacognosy -Pharmaceutical Biology at the Department of Pharmacognosy (University of Vienna, Austria) and was appointed to act as a Department Head (Department of Molecular Biology) at the Institute of Genetics and Animal Breeding of the Polish Academy of Sciences (Jastrzebiec, Poland).
Some representative scientific works byProf. Atanasov are:
- Atanasov AG*, Waltenberger B, Pferschy-Wenzig EM, Linder T, Wawrosch C, UhrinP, Temml V, Wang L, Schwaiger S, Heiss EH, Rollinger JM, Schuster D, Breuss JM,Bochkov V, Mihovilovic MD, Kopp B, Bauer R, Dirsch VM, Stuppner H. Discovery and resupply of pharmacologically active plant-derived natural products: A review.Biotechnol Adv. 2015 Dec;33(8):1582-614. doi: 10.1016/j.biotechadv.2015.08.001.https://www.ncbi.nlm.nih.gov/pubmed/26281720
- Waltenberger B, Mocan A, Šmejkal K, Heiss EH, Atanasov AG*. Natural Products toCounteract the Epidemic of Cardiovascular and Metabolic Disorders. Molecules.2016 Jun 22;21(6). pii: E807. doi:10.3390/molecules21060807. https://www.ncbi.nlm.nih.gov/pubmed/27338339
- Liu R, Heiss EH, Sider N, Schinkovitz A, Gröblacher B, Guo D, Bucar F, Bauer R, Dirsch VM, Atanasov AG*. Identification and characterization of -shogaol from ginger as inhibitor of vascular smooth muscle cell proliferation. MolNutr Food Res. 2015 Jan 28. doi: 10.1002/mnfr.201400791. http://www.ncbi.nlm.nih.gov/pubmed/25631547
- Wang L, Waltenberger B, Pferschy-Wenzig EM, Blunder M, Liu X, Malainer C, Blazevic T, Schwaiger S, Rollinger JM, Heiss EH, Schuster D, Kopp B, Bauer R, Stuppner H, Dirsch VM, Atanasov AG*. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPAR?): a review. BiochemPharmacol. 2014 Nov 1;92(1):73-89. Review. doi: 10.1016/j.bcp.2014.07.018. http://www.ncbi.nlm.nih.gov/pubmed/25083916
- Fakhrudin N, Waltenberger B, Cabaravdic M, Atanasov AG*, Malainer C, Schachner D, Heiss EH, Liu R, Noha SM, Grzywacz AM, Mihaly-Bison J, Awad EM, Schuster D, Breuss JM, Rollinger JM, Bochkov V, Stuppner H, Dirsch VM. Identification of plumericin as a potent new inhibitor of the NF-kappaB pathway with anti-inflammatory activity in vitro and in vivo. Br J Pharmacol. 2014 Apr;171(7):1676-86. doi: 10.1111/bph.12558. http://www.ncbi.nlm.nih.gov/pubmed/24329519
- Fakhrudin N, Ladurner A, Atanasov AG*, Heiss EH, Baumgartner L, Markt P, Schuster D, Ellmerer EP, Wolber G, Rollinger JM, Stuppner H, Dirsch VM. Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gamma. MolPharmacol. 2010 Apr;77(4):559-66. doi: 10.1124/mol.109.062141. http://www.ncbi.nlm.nih.gov/pubmed/20064974
- Atanasov AG, Ignatova ID, Nashev LG, Dick B, Ferrari P, Frey FJ, Odermatt A. Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess. J Am SocNephrol. 2007 Apr;18(4):1262-70. http://www.ncbi.nlm.nih.gov/pubmed/17314322
- Atanasov AG, Nashev LG, Tam S, Baker ME, Odermatt A. Organotins disrupt the 11beta-hydroxysteroid dehydrogenase type 2-dependent local inactivation of glucocorticoids. Environ Health Perspect. 2005 Nov;113(11):1600-6. http://www.ncbi.nlm.nih.gov/pubmed/16263518
Prof. Atanasov has built a significant expertise not just in biomedical sciences, but also in innovative approaches of science communication in general. Selected publications by Prof. Atanasov that are exploring innovative science communication approaches are:
- Pferschy-Wenzig EM, Pferschy U, Wang D, Mocan A, Atanasov AG. Does a GraphicalAbstract Bring More Visibility to Your Paper? Molecules. 2016 Sep 18;21(9). pii: E1247. doi: 10.3390/molecules21091247. https://www.ncbi.nlm.nih.gov/pubmed/27649137
- Science visibility and the social media potency to promote it. https://www.linkedin.com/pulse/science-visibility-social-media-potency-promote-atanas-g-atanasov
More information for Prof. Atanasov is available on his webpage: https://about.me/Atanas_At
Email Address: [email protected]
Phone Number: 0048 227 367 022
Location: Jastrzebiec, Poland